Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses

• US 5,525,621 A
• Filed: 05/20/1994
• Issued: 06/11/1996
• Est. Priority Date: 05/20/1994
• Status: Expired due to Fees

• Current Assignee: Cytos Pharmaceuticals LLC
• Original Assignee: Cytos Pharmaceuticals LLC
• Inventors: Collins, Jack R., Burt, Stanley
• Primary Examiner(s): Haley, Jacqueline
• Application Number:
  US08/246,419
• Time in Patent Office: 753 Days
• Field of Search: 514/393, 514/397, 548/312.7, 548/302.1
• US Class Current: 514/393
• CPC Class Codes: C07D 233/64 with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
• CPC Class Codes: C07D 233/88 Nitrogen atoms, e.g. allantoin

Abstract

Compounds of the formula ##STR1## wherein the substituents are as defined in the disclosure. The compounds are particularly useful for inhibiting damage to a variety of mammalian tissue that are jeopardized, for example, during runaway inflammatory conditions due to the damaging presence of singlet oxygen, the hydroxyl radical, cytokines and growth factors. The compounds are also useful in inhibiting damage to cardiac and central nervous system tissues during reperfusion.

Claims

1. A method for inhibiting or treating reperfusion injury in a mammalian organism in need of such treatment, said method comprising administering to said mammal an amount of an imidazole derivative effective in the inhibition or treatment of reperfusion injury, said imidazole derivative having the formula:

##STR6## wherein R₁ and R₂ are selected from the group consisting of hydrogen and normal, secondary, branched and tertiary C_1-18 alkyl groups;

X is a heteroatom selected from the group consisting of oxygen and sulfur;

Q is selected from the group consisting of --(CH₂)--_n, --(CH)--_n ##STR7## and m=0 or 1

p=0 or 1 n=1-18

x=y=0-3

s=1-3

t=1-3

with the proviso that when p=0 then m=1 and the imidazole rings are joined together by a single bond to make a fused tricyclic ring, and when m=0 then p=1.

2. The method of claim 1 wherein said imidazole derivative is N,N'"'"'-di(5-imidazolyl) urea.

3. The method of claim 1 wherein said imidazole derivative is di(5-imidazoyl methyl) ketone.

4. The method of claim 1 wherein said imidazole derivative is bis 2,3-4,5 imidazo furan.

5. The method of claim 1 wherein said imidazole derivative is 2,5-di(-5-imidazolyl) cyclopentadien-1-one.

6. The method of claim 1 wherein said imidazole derivative is 1,2-di(5-imidazolyl) ethane.

7. A method of controlling at least one of ventricular tachycardia, ventricular fibrillation, and ultrastructural damage to or infarction of coronary and cardiac tissue, comprising the step of providing to said tissue an amount of an imidazole derivative effective to prevent tachycardia or fibrillation, ultrastructural damage to or infarction of said tissues, said imidazole derivative having the formula:

##STR8## wherein R₁ and R₂ are selected from the group consisting of hydrogen and normal, secondary, branched and tertiary C_1-18 alkyl groups;

X is a heteroatom selected from the group consisting of oxygen and sulfur;

Q is selected from the group consisting of --(CH₂)--_n, --(CH)--_n ##STR9## and m=0 or 1

p=0 or 1

n=1-18

x=y=0-3

s=1-3

t=1-3

with the proviso that when p=0 then m=1 and the imidazole rings are joined together by a single bond to make a fused tricyclic ring, and when m=0 then p=1.

8. The method of claim 7 wherein said imidazole derivative is N,N'"'"' di(5-imidazolyl) urea.

9. The method of claim 7 wherein said imidazole derivative is di(5-imidazolyl methyl) ketone.

10. The method of claim 7 wherein said imidazole derivative is bis 2,3-4,5 imidazo furan.

11. The method of claim 7 wherein said imidazole derivative is 2,5 di(-5-imidazolyl) cyclopentadien-1-one.

12. The method of claim 7 wherein said imidazole derivative is 1,2 di(5-imidazolyl) ethane.

13. A method for treating runaway inflammatory responses in a mammalian organism in need of such treatment, said method comprising administering to said mammal an effective amount of an imidazole derivative having the formula:

##STR10## wherein R₁ and R₂ are selected from the group consisting of hydrogen and normal, secondary, branched and tertiary C_1-18 alkyl groups;

X is a heteroatom selected from the group consisting of oxygen and sulfur;

Q is selected from the group consisting of --(CH₂)--_n, --(CH)--_n ##STR11## and m=0 or 1

p=0 or 1

n=1-18

x=y=0-3

s=1-3

t=1-3

with the proviso that when p=0 then m=1 and the imidazole rings are joined together by a single bond to make a fused tricyclic ring, and when m=0 then p=1.

14. The method of claim 13 wherein said imidazole derivative is N,N'"'"' di(5-imidazolyl) urea.

15. The method of claim 13 wherein said imidazole derivative is di(5-imidazolyl methyl) ketone.

16. The method of claim 13 wherein said imidazole derivative is bis 2,3-4,5 imidazo furan.

17. The method according to claim 13, wherein the runaway inflammatory conditions are selected from heart attack, stroke, subarachnoid hemorrhage, head injury, spinal cord injury, burns, wounds, asthma, septic shock, adult respiratory distress syndrome, bacterial meningitis and inflammatory bowel conditions and further wherein said imidazole derivatives inhibit tissue damage caused by cytokines and growth factors from runaway inflammatory condition and chemotactic cascades produced during surgical procedures.

18. The method of claim 17 wherein said imidazole derivative is N,N'"'"'-di(5-imidazolyl) urea.

19. The method of claim 13 wherein said imidazole derivative is 2,5 di(-5-imidazolyl) cyclopentadien-1-one.

20. The method of claim 13 wherein said imidazole derivative is 1,2 di(5-imidazolyl) ethane.

21. The method of claim 17 wherein said imidazole derivative is di(5-imidazoyl methyl) ketone.

22. The method of claim 17 wherein said imidazole derivative is bis 2,3-4,5 imidazo furan.

23. The method of claim 17 wherein said imidazole derivative is 2,5-di(-5-imidazolyl) cyclopentadien-1-one.

24. The method of claim 17 wherein said imidazole derivative is 1,2-di(5-imidazolyl) ethane.

25. A method of preventing, controlling, or ameliorating the growth of undesired or abnormal tissue that occurs in a mammal following surgical procedures, said method comprising the step of administering a therapeutically effective amount of an imidazole derivative having the formula:

##STR12## wherein R₁ and R₂ are selected from the group consisting of hydrogen and normal, secondary, branched and tertiary C_1-18 alkyl groups;

X is a heteroatom selected from the group consisting of oxygen and sulfur;

Q is selected from the group consisting of --(CH₂)--_n, --(CH)--_n ##STR13## and m=0 or 1

p=0 or 1

n=1-18

x=y=0-3

s=1-3

t=1-3

with the proviso that when p=0 then m=1 and the imidazole rings are joined together by a single bond to make a fused tricyclic ring, and when m=0 then p=1.

26. The method of claim 25 wherein the growth of undesired or abnormal tissue results from at least one of retenosis following angioplasty and atherosclerotic plaque within a vessel.

27. The method of claim 25 wherein the vessel comprises a man-made vascular graft.

28. The method of claim 25 wherein said imidazole derivative is N,N'"'"'-di(5-imidazolyl) urea.

29. The method of claim 25 wherein said imidazole derivative is di(5-imidazolyl methyl) ketone.

30. The method of claim 25 wherein said imidazole derivative is bis 2,3-4,5 imidazo furan.

31. The method of claim 25 wherein said imidazole derivative is 2,5-di(-5-imidazolyl) cyclopentadien-1-one.

32. The method of claim 25 wherein said imidazole derivative is 1,2-di(5-imidazolyl) ethane.

33. A method of ameliorating damage to mammalian central nervous system tissue, cells, or vessels, comprising the step of administering to a mammalian subject in need thereof an effective amount of an imidazole derivative having the formula:

##STR14## wherein R₁ and R₂ are selected from the group consisting of hydrogen and normal, secondary, branched and tertiary C_1-18 alkyl groups;

X is a heteroatom selected from the group consisting of oxygen and sulfur;

Q is selected from the group consisting of --(CH₂)--_n, --(CH)--_n ##STR15## and m=0 or 1

p=0 or 1

n=1-18

x=y=0-3

s=1-3

t=1-3

with the proviso that when p=0 then m=1 and the imidazole rings are joined together by a single bond to make a fused tricyclic ring, and when m=0 then p=1.

34. The method of claim 33 wherein said imidazole derivative is N,N'"'"'-di(5-imidazolyl) urea.

35. The method of claim 33 wherein said imidazole derivative is di(5-imidazoyl methyl) ketone.

36. The method of claim 33 wherein said imidazole derivative is bis 2,3-4,5 imidazo furan.

37. The method of claim 33 wherein said imidazole derivative is 2,5-di(-5-imidazolyl) cyclopentadien-1-one.

38. The method of claim 33 wherein said imidazole derivative is 1,2-di(5-imidazolyl) ethane.

39. A method of protecting mammalian tissue and cells from damaging oxygen species by administering to a mammalian subject in need thereof an effective amount of an imidazole derivative to scavenge at least one of singlet oxygen and hydroxyl radicals, said imidazole derivative having the formula:

##STR16## wherein R₁ and R₂ are selected from the group consisting of hydrogen and normal, secondary, branched and tertiary C_1-18 alkyl groups;

X is a heteroatom selected from the group consisting of oxygen and sulfur;

Q is selected from the group consisting of --(CH₂)--_n, --(CH)--_n ##STR17## and m=0 or 1

p=0 or 1

n=1-18

x=y=0-3

s=1-3

t=1-3

with the proviso that when p=0 then m=1 and the imidazole rings are joined together by a single bond to make a fused tricyclic ring, and when m=0 then p=1.

40. A method of improving mammalian vasomotor tone by administering to a mammal an amount of an imidazole derivative sufficient to protect the endothelial dependent relaxation factor (EDRF/nitric oxide) cycle, said imidazole derivative having the formula:

##STR18## wherein R₁ and R₂ are selected from the group consisting of hydrogen and normal, secondary, branched and tertiary C_1-18 alkyl groups;

X is a heteroatom selected from the group consisting of oxygen and sulfur;

Q is selected from the group consisting of --(CH₂)--_n, --(CH)--_n ##STR19## and m=0 or 1

p=0 or 1

n=1-18

x=y=0-3

s=1-3

t=1-3

with the proviso that when p=0 then m=1 and the imidazole rings are joined together by a single bond to make a fused tricyclic ring, and when m=0 then p=1.

41. The method of claim 40 wherein said imidazole derivative is N,N'"'"'-di(5-imidazolyl) urea.

42. The method of claim 40 wherein said imidazole derivative is di(5-imidazoyl methyl) ketone.

43. The method of claim 40 wherein said imidazole derivative is bis 2,3-4,5 imidazo furan.

44. The method of claim 40 wherein said imidazole derivative is 2,5-di(-5-imidazolyl) cyclopentadien-1-one.

45. The method of claim 40 wherein said imidazole derivative is 1,2-di(5-imidazolyl) ethane.

46. A pharmaceutical composition useful for inhibiting damage to jeopardized tissue during reperfusion in a mammal which comprises:

(a) a compound of the formula ##STR20## wherein R₁ and R₂ are selected from the group consisting of hydrogen and normal, secondary, branched and tertiary C_1-18 alkyl groups;

X is a heteroatom selected from the group consisting of oxygen and sulfur;

Q is selected from the group consisting of --(CH₂)--_n, --(CH)--_n ##STR21## and m=0 or 1

p=0 or 1

n=1-18

x=y=0-3

s=1-3

t=1-3

with the proviso that when p=0 then m=1 and the imidazole rings are joined together by a single bond to make a fused tricyclic ring, and when m=0 then p=1;

(b) a therapeutic agent selected from the group consisting of urokinase, streptokinase, tissue plasminogen activator and superoxide dismutase; and

(c) a pharmaceutically acceptable inert carrier.

47. A therapeutic composition for treating reperfusion injury and injury due to severe inflammatory responses in a mammal which comprises:

(a) a compound of the formula ##STR22## wherein R₁ and R₂ are selected from the group consisting of hydrogen and normal, secondary, branched and tertiary C_1-18 alkyl groups;

X is a heteroatom selected from the group consisting of oxygen and sulfur;

Q is selected from the group consisting of --(CH₂)--_n, --(CH)--_n ##STR23## and m=0 or 1

p=0 or 1

n=1-18

s=1-3

t=1-3

with the proviso that when p=0 then m=1 and the imidazole rings are joined together by a single bond to make a fused tricyclic ring, and when m=0 then p=1; and

(b) a carrier which is a biomaterial or a delivery device for direct or indirect delivery to tissue or cells in need of treatment.

48. The composition of claim 47 wherein (b) comprises liposomes timed-release capsules or tablets, hydrogel or other polymers, gels, gauzes, patches, bandages, materials suitable for artificial skin and bone, drug delivery catheters, stents, osmotic pumps, metered dose inhalers nebulizers, and aerosolizers.

49. A compound of the formula:

##STR24## wherein R₁ and R₂ are selected from the group consisting of hydrogen and normal, secondary, branched and tertiary C_1-18 alkyl groups;

X is a heteroatom selected from the group consisting of oxygen and sulfur;

Q is selected from the group consisting of --(CH)--_n ##STR25## and m=0 or 1

p=0 or 1

n=1-18

s=1-3

t=1-3

with the proviso that when p=0 then m=1 and the imidazole rings are joined together by a single bond to make a fused tricyclic ring, and when m=0 then p=1.

50. The compound of claim 49 wherein said imidazole derivative is di(5-imidazolyl methyl) ketone.

51. The compound of claim 49 wherein said imidazole derivative is bis 2,3-4,5 imidazo furan.

52. The compound of claim 49 wherein said imidazole derivative is N,N'"'"' di(5-imidazolyl) urea.

53. The compound of claim 49 wherein said imidazole derivative is 2,5 di(-5-imidazolyl) cyclopentadien-1-one.